Latest News

(UroToday.com) The treatment landscape in advanced prostate cancer has rapidly evolved. In particular, agents with demonstrated survival benefits later in the natural history of prostate cancer have been used earlier in the disease process. In the context of metastatic castration-sensitive prostate cancer (mCSPC), docetaxel was the first agent to demonstrate a survival benefit when combined with […]

(UroToday.com) The 2021 Ramon Guiteras Lecture at the 2021 American Urologic Association (AUA) annual meeting was provided by Dr. Eila Skinner who provided her perspective on three decades of bladder cancer treatment and advances. Dr. Skinner started by highlighting what bladder cancer was like in 1990, noting that there was an understanding of the basic epidemiology […]

(UroToday.com) The treatment landscape in advanced prostate cancer has rapidly evolved. Docetaxel was the first agent to demonstrate a survival benefit in metastatic castration resistant prostate cancer (mCRPC) and has subsequently demonstrated benefit in metastatic castration-sensitive disease. However, the optimal use of docetaxel is not clear and it may be underutilized. Thus, biomarkers and prediction models […]

(UroToday.com) The treatment landscape in advanced prostate cancer has rapidly evolved. In the context of metastatic castration resistant prostate cancer (mCRPC), docetaxel was the first agent to demonstrate a survival benefit when combined with conventional androgen deprivation therapy (ADT). Following this, a number of androgen receptor targeting agents have been assessed, beginning with abiraterone acetate. More […]

(UroToday.com) The treatment landscape in advanced prostate cancer has rapidly evolved. In the context of metastatic castration resistant prostate cancer (mCRPC), docetaxel was the first agent to demonstrate a survival benefit when combined with conventional androgen deprivation therapy (ADT). Following this, a number of androgen receptor targeting agents have been assessed, beginning with abiraterone acetate and […]

(UroToday.com) At the 2021 American Urologic Association (AUA) annual meeting, the advanced prostate cancer session included Dr. Fred Saad discussing the effect of relugolix versus leuprolide on castration resistance-free survival (CRFS) among men included in the phase 3 HERO study. Androgen deprivation therapy is a foundational therapy for achieving castration levels for men with advanced prostate cancer […]

(UroToday.com) At the 2021 American Urologic Association (AUA) annual meeting, Dr. Michael Fabrizio discussed real-world utilization of apalutamide and enzalutamide in non-metastatic castrate resistant prostate cancer. Management of non-metastatic castrate-resistant prostate cancer has shifted since the approval of three second-generation androgen receptor antagonists: apalutamide, enzalutamide, and darolutamide.  In clinical trials, all agents have proven to delay […]

(UroToday.com) The advanced prostate cancer session at the 2021 American Urologic Association (AUA) annual meeting included a presentation by Dr. Scott Tagawa who discussed long-term follow-up and prognostic factor analysis among men with mCRPC who received 177Lu-PSMA therapy. PSMA-targeted radionuclide therapy has recently emerged as a promising treatment modality for advanced prostate cancer. PSMA may be […]

(UroToday.com) The 2021 American Urologic Association (AUA) annual meeting included a guideline amendment update for non-muscle invasive bladder cancer (NMIBC) and muscle-invasive bladder cancer (MIBC) provided by Dr. James McKiernan. For each section of the guidelines (NMIBC and MIBC) Dr. McKiernan reviewed important guidelines highlights (that did not change in the amendment), as well as changes to […]

(UroToday.com) Most patients newly diagnosed with bladder cancer have non-muscle invasive disease (NMIBC). For patients with intermediate or high-risk NMIBC and those with carcinoma in situ (CIS), adjuvant treatment with Bacillus Calmette Guerin (BCG) is guideline-recommended on the basis of proven benefits in disease recurrence. While BCG is efficacious, many patients eventually develop BCG-unresponsive disease. […]